Pfizer upgrade to $53 $PFE The Pfizer Analyst: Cantor Fitzgerald analyst Louise Chen maintained an Overweight rating on Pfizer with a $53 price target.
The Pfizer Takeaways: The positive topline results are good news for the company, underlining Pfizer's ability to pivot and innovate quickly, Chen said in a note.
The data reinforces Cantor's positive investment thesis on the stock and view that Pfizer's pipeline is underappreciated, the analyst said.
News 
Market Data 
Discover 
